Funding for this research was provided by:
National Institutes of Health (R01CA229415)
Received: 18 March 2020
Accepted: 5 April 2020
First Online: 1 May 2020
Ethics approval and consent to participate
: Ethics approval has been obtained by Roswell Park Comprehensive Cancer Center’s Institutional Review Board (I-65718). Participants do not qualify as a vulnerable population as defined by the protection guidelines (i.e., not minors, pregnant women, under legal coercion or restriction, or mentally impaired). Participants will be competent and able to legally provide voluntary written informed consent. The consent process will inform participants in the detail of the procedures, time, involvement, compensation, risks, and treatment options other than participation in the study. Participants will also be instructed that they can withdraw from participation at any time without losing any of the compensation that they have earned to that point and that enrollment in the study will in no way adversely affect the provision of treatment elsewhere (e.g., Quitline, Roswell Park, etc.).
: Not applicable.
: The authors declare that they have no competing interests. The study received external funding from the National Institutes of Health, National Cancer Institute, as noted below.